ArticleEye (London, England)2026
Validation of Macular Telangiectasia Type-2 (MacTel) multimodal imaging-based classification system in a cohort from India.
Article in Eye (London, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTo validate the recently proposed Macular Telangiectasia Type-2 (MacTel) Classification and Regression Trees (CART)-based multimodal imaging grading by the Chew et al. MacTel research group.
methodsCross-sectional multicentre study in India. We reviewed the medical records of 1432 eyes of 733 participants from the MacTel registry of three retinal centres. Multimodal imaging analysis of colour fundus photograph, spectral-domain optical coherence tomography (SD-OCT), and fundus autofluorescence images was performed to validate the CART-based grading of MacTel. It is a decision tree where each fork is split into a predictor variable, with each node ultimately predicting the target variable at its end. To design a CART-based grading system for categories without a clear progression, multiple combinations of OCT features were explored to identify the best representation of progressive decline in best corrected visual acuity (BCVA). The primary outcome was to demonstrate whether BCVA decreases with increasing severity of MacTel as per this classification.
resultsThis seven-step severity scale correlated with BCVA in our study group. BCVA decreased in the following order from: grade 0, no OCT features were present with well-preserved BCVA, grade 1 characterized by non-central ellipsoid zone (EZ) loss, grade 2 with central EZ loss, grade 3 marked by non-central pigment, grade 4 by outer retinal hyper-reflectivity, grade 5 with central pigment, to grade 6 associated with exudative neovascularization, which may or may not include central pigment.
conclusionsOur study validates the Chew et al. classification and further reinforces the application of this grading scale in clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.